Whether to promote platelet recovery or to ameliorate the complications of cancer and the side effects of chemotherapy, hematopoietic growth factors (HGFs) now account for more than $5 billion per year of the US health care budget. In Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics, leading oncologists, hematologists, and nephrologists comprehensively review the role of HGFs in clinical practice, explain the molecular basis of their effects, and consider potential future developments. The authors focus on the use of HGFs in oncology, describing their cutting-edge application to patients with lung cancer, Hodgkin's and non-Hodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, AIDS-related malignancies, myelodysplastic syndromes, and aplastic anemias. Among the HGFs described are granulocyte colony-stimulating factor, erythropoietc factors, thrombopoietic factors, and stem-cell factor and its receptor, c-kit. To complete their survey, the contributors also consider the safety and economic implications of HGFs and the future potential for HGF antagonists in oncology.
Comprehensive and up-to-date, Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Practice offers an integrated survey of the role of HGFs in treating and preventing anemia, neutropenia, and thrombocytopenia in patients with malignant and nonmalignant diseases, along with fresh insights into drug development and how basic discoveries in this area can be optimally translated into clinical benefit.

Klappentext

Leading oncologists, hematologists, and nephrologists comprehensively review the role of HGFs in clinical practice, explain the molecular basis of their effects, and consider potential future developments. The authors focus on the use of HGFs in oncology, describing their cutting-edge application to patients with lung cancer, Hodgkin's and nonhodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, AIDS-related malignancies, myelodysplastic syndromes, and aplastic anemias. Among the HGFs described are granulocyte colony-stimulating factor, erythropoietc factors, thrombopoietic factors, and stem cell factor and its receptor, C-kit. To complete their survey, the contributors also consider the safety and economic implications of HGFs and the future potential for HGF antagonists in oncology.

Inhalt

Part I. Basic Research Introduction to Hematopoietic Growth Factors: A General Overview George Morstyn and MaryAnn Foote Animal Models of Hematopoietic Growth Factor Perturbations in Physiology and Pathology Graham J. Lieschke The Jak/Stat Pathway of Cytokine Signaling Ben A. Croker and Nicos A. Nicola Small-Molecule and Peptide Agonists: A Literature Review Ellen G. Laber and C. Glenn Begley Part II. Hematopoietic Growth Factors Granulocyte Colony-Stimulating Factor Graham Molineux Erythropoietic Factors: Clinical Pharmacology and Pharmacokinetics Steven Elliott, Anne C. Heatherington, and MaryAnn Foote Thrombopoietin Factors David J. Kuter Stem Cell Factor and Its Receptor, c-Kit Keith E. Langley Hematopoietic Growth Factors: Preclinical Studies of Myeloid and Immune Reconstitution Ann M. Farese and Thomas J. MacVittie Part III. Use of Hematopoietic Growth Factors in Oncology Commentary on the ASCO and ESMO Evidence-Based Clinical Practice Guidelines for the Use of Hematopoietic Colony-Stimulating Factors Richard M. Fox Neutropenia and the Problem of Fever and Infection in Patients With Cancer David C. Dale Thrombocytopenia and Platelet Transfusions in Patients With Cancer Lawrence T. Goodnough Hematopoietic Growth Factors in Lung Cancer Johan F. Vansteenkiste and Christophe A. Dooms Role of Hematopoietic Growth Factors As Adjuncts to the Treatment of Hodgkin's and Non-Hodgkin's Lymphomas Marcie R. Tomblyn and Jane N. Winter Use of Granulocyte Growth Factors in Breast Cancer Eric D. Mininberg and Frankie Ann Holmes Role of Cytokines in the Management of Chronic Lymphocytic Leukemia Carol Ann Long Hematopoietic Growth Factor Therapy for Myelodysplastic Syndromes and Aplastic Anemia Jason Gotlib and Peter L. Greenberg Use of Hematopoietic Growth Factors in AIDS-Related Malignancies MaryAnn Foote Part IV. Safety and Economic Implications The Safety of Hematopoietic Growth Factors Roy E. Smith and Barbara C. Good Long-Term Safety of Filgrastim in Chronic Neutropenias Karl Welte Economics of Hematopoietic Growth Factors Gary H. Lyman and Nicole M. Kuderer Part V. Future Directions Potential for Hematopoietic Growth Factor Antagonists in Oncology Hayley S. Ramshaw, Timothy R. Hercus, Ian N. Olver, and Angel F. Lopez Acronyms and Selected Abbreviations Index